Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety
about
Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathwaysDesign and synthesis of truncated 4'-thioadenosine derivatives as potent and selective A3 adenosine receptor antagonists.Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.Synthesis and Binding Affinity of Homologated Adenosine Analogues as A3 Adenosine Receptor Ligands.Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonistsSelective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.Synthesis of 2-chloro-N6-substituted-4'-thioadenosine-5'-N, N-dialkyluronamides as potent and selective A3 adenosine receptor antagonists.Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species.The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Design, synthesis, and anti-tumor activity of 4'-thionucleosides as potent and selective agonists at the human A3 adenosine receptor.Stereoselective synthesis of 1'-functionalized-4'-thionucleosides.Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study.A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.
P2860
Q24646643-94100762-5D68-4DBF-B496-B9162CBDA2D4Q34990852-57F7C434-ECC9-4D79-AFBA-4D0EE5529337Q35029175-EA4F4678-5956-47D7-87B0-809459054B91Q35774202-6BE8EC9B-3189-45C2-B23E-5C5AACFE64F7Q36146803-F7BE7419-E5F3-40E5-8232-E3F350CA5D12Q36740173-C957CB48-BF0B-4E06-8232-B19656337130Q36996182-5A235781-0B79-4052-BE72-07D044E7B336Q37356590-0EB9CAA8-693A-4F41-9424-8052DC721D61Q37461055-6A0BDA78-A87A-4DDB-B381-D41B205463A1Q37957791-CB7490BD-AAB7-4FAB-B072-6C5EEA5D28C5Q38503177-D1903E27-D910-428E-BE57-112465EE8CC2Q38503252-80AD725C-E925-4C16-9D9A-82007AEC1378Q38649750-1F03ACC8-2A40-46F2-9372-7672AA94FAEFQ39418010-DF5F0F8C-6416-4FFE-A77C-5EA0FE7C4AA7
P2860
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@ast
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@en
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@nl
type
label
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@ast
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@en
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@nl
prefLabel
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@ast
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@en
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@nl
P2093
P2860
P1476
Conversion of A3 adenosine rec ...... 5'-ribofuran-uronamide moiety
@en
P2093
Athena M Klutz
Bhalchandra V Joshi
Hea Ok Kim
Hyuk Woo Lee
Lak Shin Jeong
Soo-Kyung Kim
P2860
P304
P356
10.1016/J.BMCL.2005.10.054
P407
P577
2005-11-10T00:00:00Z